Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab

Saad Usmani • 8 Sep 2023
SOHO 2023
Multiple Myeloma Antibodies Teclistamab
MajesTEC‐1

Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York City, NY, shares some insights into the Phase I/II MajesTEC‐1 study (NCT03145181; NCT04557098) investigating the safety and efficacy of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma, commenting on the rates of infection observed in patients receiving various doses of this agent. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Saad Usmani

1:14
Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myeloma
Saad Usmani • 8 Sep 2023
1:43
High-risk multiple myeloma: addressing challenges and unmet needs
Saad Usmani • 8 Sep 2023
2:05
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani • 25 Aug 2022
1:37
Daratumumab vs isatuximab in the treatment of multiple myeloma
Saad Usmani • 25 Sep 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals